26 Sep 2008 12:42
ο»Ώ
|
For immediate release |
26Β SeptemberΒ 2008 |
ABCAM PLC
("Abcam" or "the Company")
Shareholding
Cambridge UK,Β 26Β SeptemberΒ 2008: AbcamΒ plc announces thatΒ in accordance with the FSA's Disclosure and Transparency Rules,Β the CompanyΒ wasΒ notifiedΒ on 25 September 2008Β that,Β as atΒ 25Β SeptemberΒ 2008,Β NW Brown Nominees LimitedΒ had an indirectΒ interestΒ in voting rights overΒ 3,960,500Β ordinary shares of 1p each in the CompanyΒ amounting to approximatelyΒ 11.28%Β of the issued shareΒ capital of the Company.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeff Iliffe, Chief Financial Officer www.abcam.com |
|
|
Numis Securities |
+ 44 (0) 20 7776 1500 |
|
Michael Meade / Nick Westlake (Nominated Adviser) James BlackΒ (Corporate Broking) |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark CourtΒ / Mary-Jane Johnson |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered inΒ Cambridge,Β UK, with aΒ USΒ office located inΒ Cambridge,Β MassachusettsΒ and a Japanese office inΒ Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality andΒ commercially viable. Abcam now has an online catalogue of over 45,000Β products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employsΒ approximatelyΒ 184Β staff in its three operating companies.
Follow the stocks